Search results
Showing 1 to 15 of 15 results for evolocumab
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Implementation of NICE TA393/394 in a tertiary Lipid Clinic - the first three years experience
lipid clinic service to adopt the NICE Technology Appraisal guidance for Evolocumab and Alirocumab. As part of the adoption project they...
Innovative Medicines Optimisation Clinic for PCSK9 inhibitors & Statin Intolerance
of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) Evolocumab & Alirocumab in primary hypercholesterolaemia and...
In development [GID-TA10655] Expected publication date: 11 September 2024
Awaiting development [GID-TA11482] Expected publication date: TBC
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Familial hypercholesterolaemia: identification and management (CG71)
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
NICE approves ground-breaking cholesterol-lowering drug inclisiran
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.
Thousands with high cholesterol set to benefit from new treatment on the NHS
Thousands of people with high cholesterol will soon have access to a new treatment option on the NHS as a result of final NICE guidance published today (28 April 2021).